

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 53722

Title: Immunotherapy - new perspective in lung cancer

Reviewer's code: 03656580

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Postdoc, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Brazil

Manuscript submission date: 2019-12-29

Reviewer chosen by: Jie Wang

Reviewer accepted review: 2020-01-04 02:37

Reviewer performed review: 2020-01-04 03:13

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Authors reviewed some aspects regarding immunotherapy in non-small cell lung cancer (NSCLC) and some perspectives about the use of this therapeutic modality in the adjuvant scenario and in small cell lung cancer (SCLC), including immunotherapy as first line in metastatic nonsquamous NSCLC, after at least one line in metastatic nonsquamous NSCLC, metastatic squamous NSCLC, adjuvant scenario on NSCLC and SCLC that is considered the new standard in advanced and metastatic NSCLC, with or without chemotherapy. Furthermore, either in first-line or after at least one line, immunotherapy has presented good effects. Although, almost all the trials that tested immunotherapy showed immune-mediated adverse events and even deaths, and it is expected in a near future that new treatment schemes involving immunotherapy and its combinations will improve their application in clinical practice.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 53722

Title: Immunotherapy - new perspective in lung cancer

Reviewer's code: 00503561

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Brazil

Manuscript submission date: 2019-12-29

Reviewer chosen by: Ruo-Yu Ma

Reviewer accepted review: 2020-03-25 09:31

Reviewer performed review: 2020-03-27 08:06

Review time: 1 Day and 22 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

This is a well organized, historically summarized review on important clinical trials, thus very informative and tutorial. 1. The area of uncertain or challenges (such as markers other than IHC ATLAS) would make the paper more charming to the readers. 2. I am not native speaker of English, usage of non-small (this is very familiar way with hyphen) and nonsquamous look weird. I need editorial help on the usage of non-squamous. 3. On the 6th line from the bottom in page 7, "Zhou et al. (Data) " probably some reference numbers would be there in the parenthesis.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No